Da traduttori professionisti, imprese, pagine web e archivi di traduzione disponibili gratuitamente al pubblico.
cdrom'en med euro visual identity indeholder data til gengivelse af motiver af eurosedler, mønter samt deres nationale symboler.
the euro visual identity cdrom contains data for reproduction of images of euro notes and coins, including their national faces.
europa er kun forrest med én ny teknologi, digital visual technology og er bagest med syv. det har gigantiske følger for vor beskæftigelse.
europe is only in the lead in one new technology, digital visual technology, and is lagging behind in seven others, with drastic consequences for our employment prospects.
iso fdis 16673: road vehicles — ergonomic aspects of transport information and control systems — occlusion method to assess visual distraction
iso fdis 16673: road vehicles — ergonomic aspects of transport information and control systems — occlusion method to assess visual distraction,
det primære endepunkt i ra-studie vi og vii var smerte ved injektionsstedet umiddelbart efter injektion målt på en 0-10 cm vas (visual analog skala).
the primary endpoint in ra studies vi and vii was injection site pain immediately after injection as measured by a 0-10 cm vas.
iso 15008 (2003): road vehicles — ergonomic aspects of transport information and control systems — specification and compliance procedures for in-vehicle visual presentation
iso 15008 (2003): road vehicles — ergonomic aspects of transport information and control systems — specification and compliance procedures for in-vehicle visual presentation,
i både marina og anchor studierne, blev de forbedringer, der blev set i synsstyrken med lucentis 0, 5 mg ved 12 måneder, overført til patient-rapporterede fordele.disse fordele blev målt på de tre delskalaer af national eye institue visual function questionnaire (vfq-25) , som var forud bestemt som sekundære endepunkter (læsesyn, afstandssyn, og synsspecifik afhængighed) .
in both the marina and anchor studies, the improvement in visual acuity seen with lucentis 0.5 mg at 12 months translated into patient-reported benefits as measured on the three subscales of the national eye institute visual function questionnaire (vfq-25) which were pre-specified secondary efficacy endpoints (near activities, distance activities, and vision-specific dependency) .